Laser Speckle Imaging Chip for Telehealth Applications

用于远程医疗应用的激光散斑成像芯片

• 批准号: 8713773
• 负责人: Matthew Jason Brooke
• 金额: $ 32.31万
• 依托单位: VASOPTIC MEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8713773
• 关键词: Affect; Age; Alzheimer' s Disease; Angiogenesis Inhibitors; Animal Model; Biomedical Engineering; Biomedical Research; Blood Vessels; Blood flow; Burn injury; Caliber; Cardiovascular Diseases; Characteristics; Classification; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collection; Communities; Computer software; Computers; Consumption; Contrast Media; Custom; Data; Development; Devices; Diabetic Retinopathy; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease Management; Disease Outcome; Disease Progression; Dyes; Ear; Early Diagnosis; Elderly; Engineering; Environment; Evaluation; Family suidae; Fluorescein Angiography; Functional disorder; Goals; Healed; Health; Health Care Costs; Health Personnel; Healthcare Systems; Home environment; Hypertension; Hypertensive Retinopathy; Image; Imaging Techniques; Imaging technology; Individual; Injury; Intellectual Property; Intervention; Investments; Lasers; Legal patent; Light; Lighting; Long-Term Effects; Marketing; Medical; Medical Economics; Medical Research; Modeling; Monitor; Mus; Noise; Optics; Oryctolagus cuniculus; Outcome; Patients; Peptides; Performance; Phase; Pre-Clinical Model; Prevention strategy; Primary Health Care; Process; Research; Research Personnel; Resolution; Resources; Retina; Retinal; Retinal Diseases; Risk; Semiconductors; Signal Transduction; Skiing; Skin; Skin Tissue; Small Business Innovation Research Grant; Speed; Stroke; Structure; Structure of central vein of the retina; Symptoms; System; Systems Integration; Technology; Therapeutic Intervention; Time; Tissues; Titrations; Topical application; Universities; Validation; Vascular Diseases; Wound Healing; aging population; angiogenesis; base; blood flow measurement; charge coupled device camera; clinical practice; commercial application; cost; density; design; diabetic; healing; image processing; in vivo; innovation; instrument; melanoma; metal oxide; miniaturize; novel; operation; optical imaging; phase 2 study; point of care; pre-clinical; pre-clinical research; pressure; programs; public health relevance; research study; software systems; telehealth; tool; transmission process; treatment effect; treatment strategy; tumor; wound

ABSTRACT There is a strong unmet need for a low-cost and convenient technology that can assist researchers and healthcare personnel in gathering vascular data. Such vascular imaging technology could assist in the short term, clinical research on the diagnostics, disease progression and effect of treatment/prevention strategies. In the long term, the same technology could integrate into the healthcare system for diagnosis, monitoring and management of disease in primary care environments, especially relevant for the aging population that may have restricted mobility. Diseases that are thought to show vascular symptoms or manifestations in the retina include diabetic/hypertensive retinopathies, stroke, cardiovascular disease and Alzheimer's disease. Skin vasculature could be monitored for identification of melanomas, classification of wounds/burns, assessment of healing, and titration of therapy (through evaluation of skin vasculature). Our team has developed an optical imaging platform based on laser speckle contrast imaging (LSCI) technology that can, for the first time, probe individual microvessels for their diameters, local density, and blood flow over a large field of view without the need for any contrast agents. Vasoptic Medical, Inc. is seeking to develop further and commercialize this technology, originally created at Johns Hopkins University, in an effort to make vascular imaging low-cost and available to clinicians, healthcare workers, and researchers at large. Specifically in this Phase I, we will develop and make available to researchers: (a) a powerful LSCI-based software suite that can image blood vessel diameters, density and flow and enable comparison in longitudinal experiments. (b) a low-cost and portable implementation of the LSCI platform (ezLSCI) by designing a novel complementary metal oxide semiconductor (CMOS) imager chip that will match the sensitivity, noise, and resolution characteristics of current CCD cameras while offering considerable improvements in power consumption, size, speed, and system integration. An FPGA-based system operational module will control the device operation including illumination, image processing and image storage/transmission. The performance of the ezLSCI system and software will be characterized in preclinical models of retinal imaging and skin imaging. The ability of the ezLSCI system to discriminate healthy retinal blood flow from decreased retinal blood flow, common in disease conditions, will be demonstrated through the systemic administration of a vasoconstrictive agent. Further, the ability of the ezLSCI system to monitor the effects of therapeutic interventions will be demonstrated in a skin wound healing model with topical administration of an anti-angiogenic agent. Upon successful completion of Phase I milestones, our Phase II effort will comprise a more rigorous validation of the ezLSCI for skin imaging in a porcine model and a proof-of-concept clinical study with due regulatory approvals. We will seek private investment to support a clinical study that investigates the use of ezLSCI for early detection of retinopathy.

摘要 有一个强烈的未满足的需要，低成本和方便的技术，可以帮助研究人员和医疗保健 收集血管数据的人员。 这种血管成像技术可以在短期内帮助临床研究， 关于诊断、疾病进展和治疗/预防策略的效果。 从长远来看，同样 技术可以整合到医疗保健系统中，用于诊断，监测和管理初级疾病， 护理环境，特别是与行动能力有限的老龄人口有关。 的疾病 被认为在视网膜中显示血管症状或表现的疾病包括糖尿病/高血压视网膜病，中风， 心血管疾病和阿尔茨海默病。 可以监测皮肤脉管系统以识别黑色素瘤， 伤口/烧伤的分类、愈合的评估和治疗的滴定（通过评估皮肤脉管系统）。 我们的团队开发了一种基于激光散斑对比度成像（LSCI）技术的光学成像平台， 第一次，探测单个微血管的直径，局部密度，以及大范围的血流。 不需要任何造影剂。 Vasoptic Medical，Inc. 正在寻求进一步发展和商业化 这项技术最初是由约翰霍普金斯大学发明的，目的是使血管成像成本低， 可供临床医生、医护人员和广大研究人员使用。 具体而言，在第一阶段，我们将开发并向研究人员提供： (a)一个强大的基于LSCI的软件套件，可以对血管直径、密度和流量进行成像， 纵向实验比较。 (b)通过设计一种新型的互补金属， 氧化物半导体（CMOS）成像器芯片，将匹配的灵敏度，噪声和分辨率特性， 同时在功耗、尺寸、速度和系统方面提供了相当大的改进 一体化基于FPGA的系统操作模块将控制设备操作，包括照明， 图像处理和图像存储/传输。 ezLSCI系统和软件的性能将在视网膜成像的临床前模型中表征， 皮肤成像 ezLSCI系统区分健康视网膜血流与减少的视网膜血流的能力 血流，常见于疾病状态，将通过全身给予血管收缩剂来证明。 剂此外，ezLSCI系统监测治疗干预效果的能力将得到证明 在局部施用抗血管生成剂的皮肤伤口愈合模型中。 在成功完成第一阶段的里程碑后，我们的第二阶段工作将包括更严格地验证 ezLSCI用于猪模型中的皮肤成像和概念验证临床研究，并获得适当的监管批准。我们将 寻求私人投资，以支持一项临床研究，调查使用ezLSCI早期发现视网膜病变。